Neuropsychological and cognitive profile in adults with migraine
Official title: Neuropsychological Profile Characterization in Patients With Migraine: Cognitive Functioning and Psychological Variables
Run by Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta · NCT07233941 · Data updated 2026-11-12
This project will test how thinking skills and psychological factors (like anxiety, depression, worry, and coping) relate to migraine in adults who have had migraine for at least one year.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 65 Years |
| Sex | All |
| Enrollment | 150 (estimated) |
| Sponsor | Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta Academic / other |
| Locations | 1 site (Milan) |
| Status | Recruiting |
| Started | September 1, 2025 |
| Main results expected | May 2027 |
| Study ends | May 2027 |
| Registry record updated | February 11, 2026 |
| Trial ID | NCT07233941 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18–65 with an ICHD-3 diagnosis of migraine for at least one year, stable treatment for three months, able to understand Italian, and without severe medical/psychiatric disorders or substance abuse are ideal candidates.
✕Probably not a fit
People with severe psychiatric illnesses, a history of alcohol or drug abuse, primary sensory deficits, or those who cannot understand Italian are unlikely to benefit from or be eligible for this protocol.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study will perform standardized neuropsychological testing and collect measures of anxiety, depressive symptoms, pain catastrophizing, excessive worry, and coping strategies in people with migraine. Investigators will examine how cognitive functioning relates to migraine clinical features, attack phase (prodromal, ictal, interictal), current pharmacological treatment, and detoxification in cases of medication overuse headache. Eligible participants are adults 18–65 with an ICHD-3 migraine diagnosis and stable treatment for at least three months, excluding those with severe psychiatric or medical comorbidities, substance abuse, or primary sensory deficits. All assessments are conducted at Fondazione IRCCS Istituto Neurologico Carlo Besta in Milan, Italy, using validated instruments and standardized protocols.
Why it matters
Potential benefit: If successful, the findings could help identify cognitive and psychological patterns linked to migraine and guide more personalized management strategies.
How similar studies have gone: Previous observational research has reported mixed evidence of cognitive changes in people with migraine, so this study builds on existing but not definitive findings.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Written informed consent. * Patients aged between 18 and 65 years. * Diagnosis of migraine according to the International Classification of Headache Disorders (ICHD-3) criteria. * Patients with a history of migraine for at least one year, to ensure the stability of the condition. * Stability of ongoing treatment for at least 3 months at baseline. * Understanding of the Italian language. Exclusion Criteria: * Severe medical or psychiatric conditions (depression, schizophrenia, psychosis) documented by specific previous diagnoses. * A history of alcohol or drug abuse. * Primary sensory deficits.
Where it's running
-
Fondazione IRCCS Istituto Neurologico Carlo Besta
Milan, Italy Recruiting
Study contacts
- Principal investigator: Danilo A Montisano, MD — Fondazione IRCCS Istituto Neurologico Carlo Besta
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Gepants for Acute Migraine in the Emergency Department
This study tests whether rimegepant or zavegepant given in the ED can relieve an acute migraine for adults.
-
Oral caffeine to reduce pain during acute migraine attacks
This test will see if a single 200 mg oral caffeine tablet taken during an acute migraine can reduce pain for adults with episodic or chronic migraine with or without aura.
-
Comparing EEG indicators to assess mindfulness therapy for migraine relief
This study is testing if mindfulness therapy can help people with frequent migraines feel better by looking at brain activity and using wearable devices to track progress at home.
-
Aerobic exercise to improve sensory, muscle, and psychosocial symptoms in women with migraine
This trial will test whether supervised aerobic exercise plus one pain neuroscience education session helps women aged 18–48 with migraine reduce disability and improve sensory, musculoskeletal, and psychosocial symptoms.
-
Remote electrical neuromodulation to test pain inhibition in migraine and fibromyalgia
We’re testing if the Nerivio wearable can boost the body’s natural pain-inhibition system (CPM) and reduce pain more than a sham device in adults with migraine or fibromyalgia.
-
Elismetrep (K-304) for acute treatment of migraine
This study tests whether a single dose of elismetrep can quickly lessen the pain of a migraine compared with placebo in adults 18 to 75.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.